BioMarin Pharmaceutical Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $1.17B | $3.94B | $348.2M |
| Jun 2017 | $1.22B | $4.02B | $354.9M |
| Sep 2017 | $1.77B | $4.58B | $431.4M |
| Dec 2017 | $1.82B | $4.63B | $598.0M |
| Mar 2018 | $1.79B | $4.60B | $474.0M |
| Jun 2018 | $1.74B | $4.62B | $427.4M |
| Sep 2018 | $1.78B | $4.70B | $882.2M |
| Dec 2018 | $1.46B | $4.43B | $494.0M |
| Mar 2019 | $1.50B | $4.44B | $364.4M |
| Jun 2019 | $1.43B | $4.39B | $307.6M |
| Sep 2019 | $1.48B | $4.56B | $423.2M |
| Dec 2019 | $1.57B | $4.69B | $437.4M |
| Mar 2020 | $1.48B | $4.72B | $476.6M |
| Jun 2020 | $2.07B | $5.30B | $818.9M |
| Sep 2020 | $2.10B | $6.16B | $1.02B |
| Dec 2020 | $1.74B | $5.85B | $649.2M |
| Mar 2021 | $1.64B | $5.81B | $667.3M |
| Jun 2021 | $1.66B | $5.90B | $641.5M |
| Sep 2021 | $1.71B | $5.98B | $617.1M |
| Dec 2021 | $1.74B | $6.00B | $587.3M |
| Mar 2022 | $1.67B | $6.06B | $605.4M |
| Jun 2022 | $1.64B | $6.15B | $619.8M |
| Sep 2022 | $1.70B | $6.26B | $761.5M |
| Dec 2022 | $1.77B | $6.38B | $724.5M |
| Mar 2023 | $1.77B | $6.43B | $580.1M |
| Jun 2023 | $1.78B | $6.56B | $694.4M |
| Sep 2023 | $1.86B | $6.76B | $785.4M |
| Dec 2023 | $1.89B | $6.84B | $755.1M |
| Mar 2024 | $1.80B | $6.87B | $747.0M |
| Jun 2024 | $1.78B | $7.07B | $972.2M |
| Sep 2024 | $1.44B | $6.85B | $675.4M |
| Dec 2024 | $1.33B | $6.99B | $942.8M |
| Mar 2025 | $1.35B | $7.15B | $1.05B |
| Jun 2025 | $1.43B | $7.46B | $1.21B |
| Sep 2025 | $1.56B | $7.61B | $1.25B |
| Dec 2025 | $1.51B | $7.59B | $1.31B |
| Mar 2026 | $2.38B | $8.59B | $2.22B |
| Jun 2026 | $5.40B | $11.72B | $874.0M |